Our Science

Our Science

Obsidian’s proprietary cytoDRiVE™ platform provides, for the first time, a technology to develop a new generation of cell and gene therapies in which the level and timing of protein activity are fully controlled in a dose-dependent manner by an FDA-approved small molecule drugs.